Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Lung Neoplasms 21Multiple Myeloma 20Neoplasm Metastasis 18Lymphoma 16Leukemia, Myeloid, Acute 15Breast Neoplasms 14Prostatic Neoplasms 12Colorectal Neoplasms 12Carcinoma, Non-Small-Cell Lung 12Ovarian Neoplasms 11Melanoma 10Glioma 10Fallopian Tube Neoplasms 10Urinary Bladder Neoplasms 9Pancreatic Neoplasms 9Triple Negative Breast Neoplasms 8Sarcoma 8Carcinoma, Renal Cell 8Medulloblastoma 7Cholangiocarcinoma 7Burkitt Lymphoma 7Small Cell Lung Carcinoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Oropharyngeal Neoplasms 6Leukemia, Lymphocytic, Chronic, B-Cell 6Leukemia, Biphenotypic, Acute 6Glioblastoma 6Endometrial Neoplasms 6Carcinosarcoma 6Uterine Cervical Neoplasms 5

Interventions

luprolide acetate gel depot 1exemestane 1darolutamide 1X-Rays 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Leuprolide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Granulosa cell tumor of the ovary × Specimen Handling × Clear all
NCT06169124 2026-05-13

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
37 enrolled

Granulosa cell tumor of the ovary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡